Tibet Rhodiola Pharmaceutical Holding Co (600211) — Capital Reinvestment Ratio
Tibet Rhodiola Pharmaceutical Holding Co (600211) has a Capital Reinvestment Ratio of 0.02x as of December 2025, meaning it reinvests 0% of its operating cash flow (CN¥297.86 Million) in capital expenditures (CN¥4.98 Million). See Tibet Rhodiola Pharmaceutical Holding Co balance sheet independence to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Tibet Rhodiola Pharmaceutical Holding Co Capital Reinvestment Ratio (1999–2025)
This chart tracks Tibet Rhodiola Pharmaceutical Holding Co's Capital Reinvestment Ratio across 25 annual periods. Check how aggressively does Tibet Rhodiola Pharmaceutical Holding Co reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Tibet Rhodiola Pharmaceutical Holding Co (1999–2025)
Year-by-year Capital Reinvestment Ratio for Tibet Rhodiola Pharmaceutical Holding Co from 1999 to 2025. For live market cap and broader valuation context, see 600211 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.02x | CN¥1.03 Billion | CN¥15.96 Million | ▼ -58.9% |
| 2024 | 0.04x | CN¥994.79 Million | CN¥37.60 Million | ▲ +88.6% |
| 2023 | 0.02x | CN¥1.08 Billion | CN¥21.69 Million | ▼ -83.5% |
| 2022 | 0.12x | CN¥837.38 Million | CN¥101.96 Million | ▼ -89.5% |
| 2021 | 1.16x | CN¥366.53 Million | CN¥425.58 Million | ▲ +124.7% |
| 2020 | 0.52x | CN¥428.17 Million | CN¥221.29 Million | ▲ +416.4% |
| 2019 | 0.10x | CN¥489.59 Million | CN¥49.00 Million | ▲ +23.9% |
| 2018 | 0.08x | CN¥289.22 Million | CN¥23.37 Million | ▼ -98.8% |
| 2017 | 6.65x | CN¥91.46 Million | CN¥607.98 Million | ▲ +17152.2% |
| 2016 | 0.04x | CN¥250.21 Million | CN¥9.64 Million | ▼ -51.6% |
| 2015 | 0.08x | CN¥133.93 Million | CN¥10.66 Million | ▼ -34.8% |
| 2013 | 0.12x | CN¥279.22 Million | CN¥34.12 Million | ▲ +55.4% |
| 2012 | 0.08x | CN¥56.20 Million | CN¥4.42 Million | ▼ -58.9% |
| 2011 | 0.19x | CN¥12.09 Million | CN¥2.31 Million | ▼ -85.9% |
| 2010 | 1.36x | CN¥1.90 Million | CN¥2.58 Million | ▲ +555.4% |
| 2009 | 0.21x | CN¥17.88 Million | CN¥3.70 Million | ▼ -7.5% |
| 2008 | 0.22x | CN¥21.46 Million | CN¥4.80 Million | ▼ -52.7% |
| 2006 | 0.47x | CN¥33.63 Million | CN¥15.90 Million | ▲ +26.5% |
| 2005 | 0.37x | CN¥18.92 Million | CN¥7.07 Million | ▼ -42.4% |
| 2004 | 0.65x | CN¥26.90 Million | CN¥17.45 Million | ▲ +33.8% |
| 2003 | 0.48x | CN¥47.20 Million | CN¥22.88 Million | ▼ -84.4% |
| 2002 | 3.11x | CN¥32.85 Million | CN¥102.14 Million | ▼ -39.7% |
| 2001 | 5.15x | CN¥15.47 Million | CN¥79.72 Million | ▼ -10.6% |
| 2000 | 5.76x | CN¥20.55 Million | CN¥118.45 Million | ▼ -79.5% |
| 1999 | 28.15x | CN¥2.25 Million | CN¥63.25 Million | — |